Says Austedo IRA price negotiations in-line with forecast. Says fundamentals of Austedo “very strong.” Expects to build momentum with biosimilars in Europe.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva says terminated exclusive discussions with select buyer for TAPI
- Teva says ‘clear path’ to 30% operating margin by 2027
- Teva says not moving forward with discussions for sale of TAPI
- Teva says net debt/EBITDA below 3.0x for first time since 2016
- Teva sees Austedo sales greater than $2.5B in 2027